newsfilter
← Latest News
PR Newswire·

Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results

Planned Phase 1a Single Ascending Dose ("SAD") clinical trial, commencing in Q2 2022, to compare fezagepras with sodiumphenylbutyrate as a nitrogen scavenger Repayment in full of the $39.1M secured loan and release of security on the Company's assets